MXPA06014236A

MXPA06014236A - Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad.

Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad.

Info

Publication number: MXPA06014236A
Authority: MX; Mexico
Prior art keywords: pde10; mice; pyrrolidin; yloxy; compound
Prior art date: 2004-06-07

Application number

MXPA06014236A

Other languages

English (en)

Spanish (es)

Inventor

Shawn Clive Black

Earl Michael Gibbs

Original Assignee

Pfizer Prod Inc

Priority date

2004-06-07

Filing date

2005-05-30

Publication date

2007-02-14

2005-05-30 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2007-02-14 Publication of MXPA06014236A publication Critical patent/MXPA06014236A/es

Links

238000011282 treatment Methods 0.000 title claims abstract description 22
208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 20
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 20
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title claims description 13
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title claims description 13
208000008589 Obesity Diseases 0.000 title description 18
235000020824 obesity Nutrition 0.000 title description 18
230000005764 inhibitory process Effects 0.000 title description 7
230000037396 body weight Effects 0.000 claims abstract description 34
210000000577 adipose tissue Anatomy 0.000 claims abstract description 27
239000003814 drug Substances 0.000 claims abstract description 22
208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 17
206010033307 Overweight Diseases 0.000 claims abstract description 14
208000002705 Glucose Intolerance Diseases 0.000 claims abstract description 13
206010018429 Glucose tolerance impaired Diseases 0.000 claims abstract description 12
229940124597 therapeutic agent Drugs 0.000 claims abstract description 8
-1 oriistat Chemical compound 0.000 claims description 64
239000005557 antagonist Substances 0.000 claims description 35
JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims description 18
229960003015 rimonabant Drugs 0.000 claims description 18
102000016267 Leptin Human genes 0.000 claims description 12
108010092277 Leptin Proteins 0.000 claims description 12
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 12
239000000883 anti-obesity agent Substances 0.000 claims description 11
229940125710 antiobesity agent Drugs 0.000 claims description 11
229940039781 leptin Drugs 0.000 claims description 11
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 10
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 10
241000282414 Homo sapiens Species 0.000 claims description 9
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 7
229960002802 bromocriptine Drugs 0.000 claims description 7
101800001672 Peptide YY(3-36) Proteins 0.000 claims description 6
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims description 6
229960004425 sibutramine Drugs 0.000 claims description 6
229960002179 ephedrine Drugs 0.000 claims description 5
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 5
229960003908 pseudoephedrine Drugs 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 3
239000003112 inhibitor Substances 0.000 abstract description 52
238000000034 method Methods 0.000 abstract description 44
241001465754 Metazoa Species 0.000 abstract description 19
230000007423 decrease Effects 0.000 abstract description 5
235000013305 food Nutrition 0.000 abstract description 4
235000013372 meat Nutrition 0.000 abstract description 4
230000001225 therapeutic effect Effects 0.000 abstract description 4
241000283690 Bos taurus Species 0.000 abstract description 2
241000287828 Gallus gallus Species 0.000 abstract description 2
241000282887 Suidae Species 0.000 abstract description 2
235000013330 chicken meat Nutrition 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 description 87
241000699670 Mus sp. Species 0.000 description 84
125000000217 alkyl group Chemical group 0.000 description 38
230000000694 effects Effects 0.000 description 32
235000009200 high fat diet Nutrition 0.000 description 31
239000003795 chemical substances by application Substances 0.000 description 25
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
235000005911 diet Nutrition 0.000 description 20
230000037213 diet Effects 0.000 description 20
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
239000000203 mixture Substances 0.000 description 19
239000000243 solution Substances 0.000 description 19
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
108090000623 proteins and genes Proteins 0.000 description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
150000003839 salts Chemical class 0.000 description 15
229910052739 hydrogen Inorganic materials 0.000 description 14
229910052757 nitrogen Inorganic materials 0.000 description 14
238000012360 testing method Methods 0.000 description 14
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
239000008103 glucose Substances 0.000 description 13
239000001257 hydrogen Substances 0.000 description 13
241000700159 Rattus Species 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
125000001072 heteroaryl group Chemical group 0.000 description 12
125000003342 alkenyl group Chemical group 0.000 description 11
239000002552 dosage form Substances 0.000 description 11
229910052736 halogen Inorganic materials 0.000 description 11
239000011541 reaction mixture Substances 0.000 description 11
239000007787 solid Substances 0.000 description 11
241000699666 Mus <mouse, genus> Species 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
239000008280 blood Substances 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
229940079593 drug Drugs 0.000 description 10
150000002367 halogens Chemical group 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
125000003545 alkoxy group Chemical group 0.000 description 9
125000003118 aryl group Chemical group 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
230000036284 oxygen consumption Effects 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
108090000765 processed proteins & peptides Proteins 0.000 description 9
238000003556 assay Methods 0.000 description 8
235000012000 cholesterol Nutrition 0.000 description 8
230000036541 health Effects 0.000 description 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 8
239000000126 substance Substances 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
125000000304 alkynyl group Chemical group 0.000 description 7
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
239000002775 capsule Substances 0.000 description 7
125000000753 cycloalkyl group Chemical group 0.000 description 7
235000012631 food intake Nutrition 0.000 description 7
230000037406 food intake Effects 0.000 description 7
238000009472 formulation Methods 0.000 description 7
229910052760 oxygen Inorganic materials 0.000 description 7
239000001301 oxygen Substances 0.000 description 7
239000000843 powder Substances 0.000 description 7
239000000651 prodrug Substances 0.000 description 7
229940002612 prodrug Drugs 0.000 description 7
239000012453 solvate Substances 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
150000003626 triacylglycerols Chemical class 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 6
108010076365 Adiponectin Proteins 0.000 description 6
102000011690 Adiponectin Human genes 0.000 description 6
229920000858 Cyclodextrin Polymers 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
239000000556 agonist Substances 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
229920000609 methyl cellulose Polymers 0.000 description 6
239000001923 methylcellulose Substances 0.000 description 6
235000010981 methylcellulose Nutrition 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
230000009467 reduction Effects 0.000 description 6
125000001424 substituent group Chemical group 0.000 description 6
125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
238000013218 HFD mouse model Methods 0.000 description 5
241000282412 Homo Species 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
238000010171 animal model Methods 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
210000002569 neuron Anatomy 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000011593 sulfur Chemical group 0.000 description 5
229910052717 sulfur Chemical group 0.000 description 5
239000003826 tablet Substances 0.000 description 5
230000004580 weight loss Effects 0.000 description 5
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
229930008281 A03AD01 - Papaverine Natural products 0.000 description 4
125000004648 C2-C8 alkenyl group Chemical group 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
102000004877 Insulin Human genes 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
102100037469 Protein DEPP1 Human genes 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
201000010099 disease Diseases 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
125000005843 halogen group Chemical group 0.000 description 4
125000005842 heteroatom Chemical group 0.000 description 4
125000000592 heterocycloalkyl group Chemical group 0.000 description 4
229940125396 insulin Drugs 0.000 description 4
125000001624 naphthyl group Chemical group 0.000 description 4
210000001577 neostriatum Anatomy 0.000 description 4
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
210000001009 nucleus accumben Anatomy 0.000 description 4
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 4
229960001243 orlistat Drugs 0.000 description 4
229960001789 papaverine Drugs 0.000 description 4
235000019271 petrolatum Nutrition 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000012216 screening Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
125000004649 C2-C8 alkynyl group Chemical group 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
102000001554 Hemoglobins Human genes 0.000 description 3
108010054147 Hemoglobins Proteins 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
238000003820 Medium-pressure liquid chromatography Methods 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
230000003281 allosteric effect Effects 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000011324 bead Substances 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000002591 computed tomography Methods 0.000 description 3
125000004093 cyano group Chemical group *C#N 0.000 description 3
238000011161 development Methods 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
235000021588 free fatty acids Nutrition 0.000 description 3
IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 3
230000006870 function Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
230000009368 gene silencing by RNA Effects 0.000 description 3
125000001188 haloalkyl group Chemical group 0.000 description 3
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000037323 metabolic rate Effects 0.000 description 3
239000002674 ointment Substances 0.000 description 3
210000001010 olfactory tubercle Anatomy 0.000 description 3
125000004430 oxygen atom Chemical group O* 0.000 description 3
239000008177 pharmaceutical agent Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 3
239000000018 receptor agonist Substances 0.000 description 3
229940044601 receptor agonist Drugs 0.000 description 3
230000000284 resting effect Effects 0.000 description 3
229960001866 silicon dioxide Drugs 0.000 description 3
239000007921 spray Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
229940032147 starch Drugs 0.000 description 3
239000008107 starch Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
125000004434 sulfur atom Chemical group 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
PBAXECCRMPYTKV-UHFFFAOYSA-N 4-(2-fluorophenyl)-6,7-dimethoxy-2-piperazin-1-ylquinazoline Chemical compound C=12C=C(OC)C(OC)=CC2=NC(N2CCNCC2)=NC=1C1=CC=CC=C1F PBAXECCRMPYTKV-UHFFFAOYSA-N 0.000 description 2
FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
208000004611 Abdominal Obesity Diseases 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
206010065941 Central obesity Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
101710150887 Cholecystokinin A Proteins 0.000 description 2
FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000015554 Dopamine receptor Human genes 0.000 description 2
108050004812 Dopamine receptor Proteins 0.000 description 2
238000008157 ELISA kit Methods 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 description 2
108010046593 Neuropeptide Y5 receptor Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
239000004147 Sorbitan trioleate Substances 0.000 description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
210000001947 dentate gyrus Anatomy 0.000 description 2
238000001514 detection method Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
201000010063 epididymitis Diseases 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
235000021050 feed intake Nutrition 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
125000002768 hydroxyalkyl group Chemical group 0.000 description 2
125000005350 hydroxycycloalkyl group Chemical group 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
235000020997 lean meat Nutrition 0.000 description 2
239000003446 ligand Substances 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000003607 modifier Substances 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
238000013116 obese mouse model Methods 0.000 description 2
238000007410 oral glucose tolerance test Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000003380 propellant Substances 0.000 description 2
210000002637 putamen Anatomy 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
235000019337 sorbitan trioleate Nutrition 0.000 description 2
229960000391 sorbitan trioleate Drugs 0.000 description 2
238000012289 standard assay Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
XCZBHNLQPSEXMT-UHFFFAOYSA-N 1-(6,7-dimethoxycinnolin-4-yl)-n-ethyl-n-methyl-4-quinolin-2-yloxypyrrolidin-3-amine Chemical compound COC1=C(OC)C=C2C(N3CC(C(C3)OC=3N=C4C=CC=CC4=CC=3)N(C)CC)=CN=NC2=C1 XCZBHNLQPSEXMT-UHFFFAOYSA-N 0.000 description 1
XEKFVNBQKROUOI-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-n,n-diethyl-4-quinoxalin-2-yloxypyrrolidin-3-amine Chemical compound COC1=C(OC)C=C2C(N3CC(C(C3)OC=3N=C4C=CC=CC4=NC=3)N(CC)CC)=NC=NC2=C1 XEKFVNBQKROUOI-UHFFFAOYSA-N 0.000 description 1
ZOWDMZQGIBBFPE-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-n,n-dimethyl-4-quinolin-2-yloxypyrrolidin-3-amine Chemical compound C1=CC=CC2=NC(OC3CN(CC3N(C)C)C=3N=CN=C4C=C(C(=CC4=3)OC)OC)=CC=C21 ZOWDMZQGIBBFPE-UHFFFAOYSA-N 0.000 description 1
WUIWXBDTSOPSFU-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-n,n-dimethyl-4-quinolin-3-yloxypyrrolidin-3-amine Chemical compound C1=CC=CC2=CC(OC3CN(CC3N(C)C)C=3N=CN=C4C=C(C(=CC4=3)OC)OC)=CN=C21 WUIWXBDTSOPSFU-UHFFFAOYSA-N 0.000 description 1
VTZPTOSOOYDDHY-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-n,n-dimethyl-4-quinoxalin-2-yloxypyrrolidin-3-amine Chemical compound C1=CC=CC2=NC(OC3CN(CC3N(C)C)C=3N=CN=C4C=C(C(=CC4=3)OC)OC)=CN=C21 VTZPTOSOOYDDHY-UHFFFAOYSA-N 0.000 description 1
DAMDNLPICKVQOF-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-n,n-dimethyl-4-quinoxalin-2-yloxypyrrolidine-2-carboxamide Chemical compound C1=CC=CC2=NC(OC3CN(C(C3)C(=O)N(C)C)C=3N=CN=C4C=C(C(=CC4=3)OC)OC)=CN=C21 DAMDNLPICKVQOF-UHFFFAOYSA-N 0.000 description 1
CANZDYINLPZLLE-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-n-ethyl-n-methyl-4-quinoxalin-2-yloxypyrrolidin-3-amine Chemical compound COC1=C(OC)C=C2C(N3CC(C(C3)OC=3N=C4C=CC=CC4=NC=3)N(C)CC)=NC=NC2=C1 CANZDYINLPZLLE-UHFFFAOYSA-N 0.000 description 1
IPOGANOWHPBERN-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-n-methyl-4-quinoxalin-2-yloxypyrrolidin-3-amine Chemical compound COC1=C(OC)C=C2C(N3CC(C(C3)OC=3N=C4C=CC=CC4=NC=3)NC)=NC=NC2=C1 IPOGANOWHPBERN-UHFFFAOYSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical group CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
DGHKCBSVAZXEPP-UHFFFAOYSA-N 2,4-dichloro-6,7-dimethoxyquinazoline Chemical compound ClC1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 DGHKCBSVAZXEPP-UHFFFAOYSA-N 0.000 description 1
YXJKFOSZPDJMPY-UHFFFAOYSA-N 2-(6,7-dimethoxyquinazolin-4-yl)-3,4-dihydro-1h-isoquinolin-7-amine Chemical compound C1CC2=CC=C(N)C=C2CN1C1=C(C=C(C(OC)=C2)OC)C2=NC=N1 YXJKFOSZPDJMPY-UHFFFAOYSA-N 0.000 description 1
DDEAEWMDOSXKBX-UHFFFAOYSA-N 2-(chloromethyl)quinoline Chemical compound C1=CC=CC2=NC(CCl)=CC=C21 DDEAEWMDOSXKBX-UHFFFAOYSA-N 0.000 description 1
JSVGRPFWXZPNFJ-UHFFFAOYSA-N 2-[1-(6,7-dimethoxyquinazolin-4-yl)-4-quinoxalin-2-yloxypyrrolidin-2-yl]propan-2-ol;hydrochloride Chemical compound Cl.C1=CC=CC2=NC(OC3CN(C(C3)C(C)(C)O)C=3N=CN=C4C=C(C(=CC4=3)OC)OC)=CN=C21 JSVGRPFWXZPNFJ-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
SEJRTTLJILPJOU-UHFFFAOYSA-N 2-chloro-4-(2-fluorophenyl)-6,7-dimethoxyquinazoline Chemical compound C=12C=C(OC)C(OC)=CC2=NC(Cl)=NC=1C1=CC=CC=C1F SEJRTTLJILPJOU-UHFFFAOYSA-N 0.000 description 1
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
KCNRIVPBPIRPBV-UHFFFAOYSA-N 2-pyrrolidin-3-yloxyquinoxaline Chemical compound C1NCCC1OC1=CN=C(C=CC=C2)C2=N1 KCNRIVPBPIRPBV-UHFFFAOYSA-N 0.000 description 1
VRWJZGHUCOFGPZ-UHFFFAOYSA-N 2-{[4-(4-pyridin-4-yl-1h-pyrazol-3-yl)phenoxy]methyl}quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1C1=NNC=C1C1=CC=NC=C1 VRWJZGHUCOFGPZ-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
UOIXJDLUBZGOMK-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)-7-methoxyquinazoline Chemical compound C1CC2=CC=CC=C2CN1C1=NC=NC2=CC(OC)=CC=C21 UOIXJDLUBZGOMK-UHFFFAOYSA-N 0.000 description 1
NNJZADJXPQFKOE-UHFFFAOYSA-N 4-(quinolin-2-ylmethoxy)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OCC1=CC=C(C=CC=C2)C2=N1 NNJZADJXPQFKOE-UHFFFAOYSA-N 0.000 description 1
VSCSTNZWXBTXLI-UHFFFAOYSA-N 4-[3-(2,3-dihydro-1h-inden-5-yloxy)pyrrolidin-1-yl]-6,7-dimethoxyquinazoline Chemical compound C1=C2CCCC2=CC(OC2CCN(C2)C=2N=CN=C3C=C(C(=CC3=2)OC)OC)=C1 VSCSTNZWXBTXLI-UHFFFAOYSA-N 0.000 description 1
LEVUGPXUDZVOIL-UHFFFAOYSA-N 4-[3-(3,4-dimethoxyphenoxy)pyrrolidin-1-yl]-6,7-dimethoxyquinazoline Chemical compound C1=C(OC)C(OC)=CC=C1OC1CN(C=2C3=CC(OC)=C(OC)C=C3N=CN=2)CC1 LEVUGPXUDZVOIL-UHFFFAOYSA-N 0.000 description 1
WUQPRMFKNDQDDT-UHFFFAOYSA-N 4-[3-(3-ethoxyphenoxy)pyrrolidin-1-yl]-6,7-dimethoxyquinazoline Chemical compound CCOC1=CC=CC(OC2CN(CC2)C=2C3=CC(OC)=C(OC)C=C3N=CN=2)=C1 WUQPRMFKNDQDDT-UHFFFAOYSA-N 0.000 description 1
DUXDVVOHXOPNKD-UHFFFAOYSA-N 4-[3-(4-ethoxyphenoxy)pyrrolidin-1-yl]-6,7-dimethoxyquinazoline Chemical compound C1=CC(OCC)=CC=C1OC1CN(C=2C3=CC(OC)=C(OC)C=C3N=CN=2)CC1 DUXDVVOHXOPNKD-UHFFFAOYSA-N 0.000 description 1
MUOKUOYNTHTOBU-UHFFFAOYSA-N 4-[[2-(6,7-dimethoxyquinazolin-4-yl)-3,4-dihydro-1h-isoquinolin-8-yl]sulfonyl]morpholine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(CC1=2)CCC1=CC=CC=2S(=O)(=O)N1CCOCC1 MUOKUOYNTHTOBU-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
LLLHRNQLGUOJHP-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 LLLHRNQLGUOJHP-UHFFFAOYSA-N 0.000 description 1
125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
IKLHKJWPKXTFLB-UHFFFAOYSA-N 4-tert-butyl-n-[2-(6,7-dimethoxyquinazolin-4-yl)-3,4-dihydro-1h-isoquinolin-7-yl]benzenesulfonamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(CC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 IKLHKJWPKXTFLB-UHFFFAOYSA-N 0.000 description 1
YXFONLAHCPMZLN-UHFFFAOYSA-N 6,7-dimethoxy-4-(3-prop-2-enyl-4-quinoxalin-2-yloxypyrrolidin-1-yl)quinazoline Chemical compound C1=CC=CC2=NC(OC3C(CC=C)CN(C3)C=3N=CN=C4C=C(C(=CC4=3)OC)OC)=CN=C21 YXFONLAHCPMZLN-UHFFFAOYSA-N 0.000 description 1
ZTOPTNRJJLNDJG-UHFFFAOYSA-N 6,7-dimethoxy-4-(3-propyl-3,4-dihydro-1h-isoquinolin-2-yl)quinazoline Chemical compound COC1=C(OC)C=C2C(N3CC4=CC=CC=C4CC3CCC)=NC=NC2=C1 ZTOPTNRJJLNDJG-UHFFFAOYSA-N 0.000 description 1
VQEVGOOIMFPGBB-UHFFFAOYSA-N 6,7-dimethoxy-4-[3-(3-phenylphenoxy)pyrrolidin-1-yl]quinazoline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C1)CCC1OC(C=1)=CC=CC=1C1=CC=CC=C1 VQEVGOOIMFPGBB-UHFFFAOYSA-N 0.000 description 1
BIKMAXFAAPMKSL-UHFFFAOYSA-N 6,7-dimethoxy-4-[3-(3-propan-2-yloxyphenoxy)pyrrolidin-1-yl]quinazoline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C1)CCC1OC1=CC=CC(OC(C)C)=C1 BIKMAXFAAPMKSL-UHFFFAOYSA-N 0.000 description 1
YCWMLVXTEBFVHL-UHFFFAOYSA-N 6,7-dimethoxy-4-[3-(7-methoxynaphthalen-2-yl)oxypyrrolidin-1-yl]quinazoline Chemical compound COC1=C(OC)C=C2C(N3CCC(C3)OC=3C=CC4=CC=C(C=C4C=3)OC)=NC=NC2=C1 YCWMLVXTEBFVHL-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
102000054930 Agouti-Related Human genes 0.000 description 1
101710127426 Agouti-related protein Proteins 0.000 description 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
101710095342 Apolipoprotein B Proteins 0.000 description 1
102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
102000018616 Apolipoproteins B Human genes 0.000 description 1
108010027006 Apolipoproteins B Proteins 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102000013585 Bombesin Human genes 0.000 description 1
108010051479 Bombesin Proteins 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
229940124802 CB1 antagonist Drugs 0.000 description 1
102100024316 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Human genes 0.000 description 1
102100024318 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B Human genes 0.000 description 1
102100024317 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C Human genes 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
101100351286 Dictyostelium discoideum pdeE gene Proteins 0.000 description 1
101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 1
101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 1
101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
102000012074 GAF domains Human genes 0.000 description 1
108050002598 GAF domains Proteins 0.000 description 1
102400001370 Galanin Human genes 0.000 description 1
101800002068 Galanin Proteins 0.000 description 1
101100295738 Gallus gallus COR3 gene Proteins 0.000 description 1
108010016122 Ghrelin Receptors Proteins 0.000 description 1
102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
102100024233 High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Human genes 0.000 description 1
102100024228 High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A Human genes 0.000 description 1
102100024229 High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B Human genes 0.000 description 1
101710145025 High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B Proteins 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
102000000543 Histamine Receptors Human genes 0.000 description 1
108010002059 Histamine Receptors Proteins 0.000 description 1
101000928179 Homo sapiens Agouti-related protein Proteins 0.000 description 1
101001117044 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Proteins 0.000 description 1
101001117099 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B Proteins 0.000 description 1
101001117094 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C Proteins 0.000 description 1
101001117267 Homo sapiens High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Proteins 0.000 description 1
101001117261 Homo sapiens High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A Proteins 0.000 description 1
101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 description 1
101001098805 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4A Proteins 0.000 description 1
101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 1
101000988423 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4C Proteins 0.000 description 1
101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
101001117266 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 7B Proteins 0.000 description 1
101001098818 Homo sapiens cGMP-inhibited 3',5'-cyclic phosphodiesterase A Proteins 0.000 description 1
101001098812 Homo sapiens cGMP-inhibited 3',5'-cyclic phosphodiesterase B Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
208000031773 Insulin resistance syndrome Diseases 0.000 description 1
229940127470 Lipase Inhibitors Drugs 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102400001132 Melanin-concentrating hormone Human genes 0.000 description 1
101800002739 Melanin-concentrating hormone Proteins 0.000 description 1
239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
206010027525 Microalbuminuria Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101000775476 Mus musculus Adiponectin Proteins 0.000 description 1
101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 1
ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
RLFMULOKGRBTMY-UHFFFAOYSA-N N1CC(CC1)OC1=NC2=CC=CC=C2N=C1.O1CCCC1 Chemical compound N1CC(CC1)OC1=NC2=CC=CC=C2N=C1.O1CCCC1 RLFMULOKGRBTMY-UHFFFAOYSA-N 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
102100027441 Nucleobindin-2 Human genes 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
229940123730 Orexin receptor antagonist Drugs 0.000 description 1
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
101150098694 PDE5A gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108010043958 Peptoids Proteins 0.000 description 1
229940123773 Phosphodiesterase 10A inhibitor Drugs 0.000 description 1
108010001441 Phosphopeptides Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
229910006080 SO2X Inorganic materials 0.000 description 1
101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000862969 Stella Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
MGXSJFSZGWPRLC-UHFFFAOYSA-N [1-(6,7-dimethoxyquinazolin-4-yl)-4-quinoxalin-2-yloxypyrrolidin-2-yl]methanol;hydrochloride Chemical compound Cl.C1=CC=CC2=NC(OC3CN(C(C3)CO)C=3N=CN=C4C=C(C(=CC4=3)OC)OC)=CN=C21 MGXSJFSZGWPRLC-UHFFFAOYSA-N 0.000 description 1
VSYMNDBTCKIDLT-UHFFFAOYSA-N [2-(carbamoyloxymethyl)-2-ethylbutyl] carbamate Chemical compound NC(=O)OCC(CC)(CC)COC(N)=O VSYMNDBTCKIDLT-UHFFFAOYSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010358 acesulfame potassium Nutrition 0.000 description 1
229960004998 acesulfame potassium Drugs 0.000 description 1
239000000619 acesulfame-K Substances 0.000 description 1
159000000021 acetate salts Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
229960002478 aldosterone Drugs 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
229940125709 anorectic agent Drugs 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
108010014210 axokine Proteins 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
239000012267 brine Substances 0.000 description 1
102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 description 1
102100037092 cAMP-specific 3',5'-cyclic phosphodiesterase 4A Human genes 0.000 description 1
102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 1
102100029169 cAMP-specific 3',5'-cyclic phosphodiesterase 4C Human genes 0.000 description 1
102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 1
102100024232 cAMP-specific 3',5'-cyclic phosphodiesterase 7B Human genes 0.000 description 1
102100037093 cGMP-inhibited 3',5'-cyclic phosphodiesterase A Human genes 0.000 description 1
102100037094 cGMP-inhibited 3',5'-cyclic phosphodiesterase B Human genes 0.000 description 1
102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
229940081733 cetearyl alcohol Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000001886 ciliary effect Effects 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
210000001653 corpus striatum Anatomy 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000000000 cycloalkoxy group Chemical group 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000018823 dietary intake Nutrition 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229940052760 dopamine agonists Drugs 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
210000001029 dorsal striatum Anatomy 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
210000004101 entopeduncular nucleus Anatomy 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
210000000918 epididymis Anatomy 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
SJFOXYHYSREIHD-UHFFFAOYSA-N ethyl 1-(6,7-dimethoxyquinazolin-4-yl)-3-methyl-4-quinoxalin-2-yloxypyrrolidine-3-carboxylate Chemical compound COC1=C(OC)C=C2C(N3CC(C(C3)OC=3N=C4C=CC=CC4=NC=3)(C)C(=O)OCC)=NC=NC2=C1 SJFOXYHYSREIHD-UHFFFAOYSA-N 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229910021485 fumed silica Inorganic materials 0.000 description 1
208000020694 gallbladder disease Diseases 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000004519 grease Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000004404 heteroalkyl group Chemical group 0.000 description 1
150000002390 heteroarenes Chemical class 0.000 description 1
125000005343 heterocyclic alkyl group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
239000003667 hormone antagonist Substances 0.000 description 1
102000055839 human AGRP Human genes 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
230000003451 hyperinsulinaemic effect Effects 0.000 description 1
201000008980 hyperinsulinism Diseases 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
238000012528 insulin ELISA Methods 0.000 description 1
210000002425 internal capsule Anatomy 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
150000003951 lactams Chemical group 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
102000005861 leptin receptors Human genes 0.000 description 1
108010019813 leptin receptors Proteins 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000012317 liver biopsy Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
CJIMBEIWORBBOQ-UHFFFAOYSA-N methyl 4-(quinolin-2-ylmethoxy)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OCC1=CC=C(C=CC=C2)C2=N1 CJIMBEIWORBBOQ-UHFFFAOYSA-N 0.000 description 1
238000010603 microCT Methods 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 1
239000008368 mint flavor Substances 0.000 description 1
SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
238000001964 muscle biopsy Methods 0.000 description 1
XRBKYHFGYDFLIQ-UHFFFAOYSA-N n-[1-(6,7-dimethoxyquinazolin-4-yl)-4-quinoxalin-2-yloxypyrrolidin-3-yl]-n-methylacetamide Chemical compound C1=CC=CC2=NC(OC3CN(CC3N(C)C(C)=O)C=3N=CN=C4C=C(C(=CC4=3)OC)OC)=CN=C21 XRBKYHFGYDFLIQ-UHFFFAOYSA-N 0.000 description 1
JPMVVTJYSRIFCD-UHFFFAOYSA-N n-[2-(6,7-dimethoxyquinazolin-4-yl)-3,4-dihydro-1h-isoquinolin-7-yl]-2,2-dimethylpropanamide Chemical compound C1CC2=CC=C(NC(=O)C(C)(C)C)C=C2CN1C1=C(C=C(C(OC)=C2)OC)C2=NC=N1 JPMVVTJYSRIFCD-UHFFFAOYSA-N 0.000 description 1
FXIZAJLEYNNCEH-UHFFFAOYSA-N n-[2-(6,7-dimethoxyquinazolin-4-yl)-3,4-dihydro-1h-isoquinolin-7-yl]-2,5-dimethylbenzenesulfonamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(CC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC(C)=CC=C1C FXIZAJLEYNNCEH-UHFFFAOYSA-N 0.000 description 1
TVHUSEDNEWKNSP-UHFFFAOYSA-N n-[2-(6,7-dimethoxyquinazolin-4-yl)-3,4-dihydro-1h-isoquinolin-7-yl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(CC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 TVHUSEDNEWKNSP-UHFFFAOYSA-N 0.000 description 1
ALNAZDLTUJSBRO-UHFFFAOYSA-N n-[2-(6,7-dimethoxyquinazolin-4-yl)-3,4-dihydro-1h-isoquinolin-7-yl]-4-ethoxybenzamide Chemical compound C1=CC(OCC)=CC=C1C(=O)NC1=CC=C(CCN(C2)C=3C4=CC(OC)=C(OC)C=C4N=CN=3)C2=C1 ALNAZDLTUJSBRO-UHFFFAOYSA-N 0.000 description 1
UHMAUBJIUGTYTC-UHFFFAOYSA-N n-[2-(6,7-dimethoxyquinazolin-4-yl)-3,4-dihydro-1h-isoquinolin-7-yl]-4-ethylbenzamide Chemical compound C1=CC(CC)=CC=C1C(=O)NC1=CC=C(CCN(C2)C=3C4=CC(OC)=C(OC)C=C4N=CN=3)C2=C1 UHMAUBJIUGTYTC-UHFFFAOYSA-N 0.000 description 1
CXPWLJYVNZFQPX-UHFFFAOYSA-N n-[2-(6,7-dimethoxyquinazolin-4-yl)-3,4-dihydro-1h-isoquinolin-7-yl]-4-propan-2-ylbenzenesulfonamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(CC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(C(C)C)C=C1 CXPWLJYVNZFQPX-UHFFFAOYSA-N 0.000 description 1
DJNSJXYEAWGFBL-UHFFFAOYSA-N n-[2-(6,7-dimethoxyquinazolin-4-yl)-3,4-dihydro-1h-isoquinolin-7-yl]acetamide Chemical compound C1CC2=CC=C(NC(C)=O)C=C2CN1C1=C(C=C(C(OC)=C2)OC)C2=NC=N1 DJNSJXYEAWGFBL-UHFFFAOYSA-N 0.000 description 1
FDFQQENXEYGEML-UHFFFAOYSA-N n-methoxy-n-methyl-4-(quinolin-2-ylmethoxy)benzamide Chemical compound C1=CC(C(=O)N(C)OC)=CC=C1OCC1=CC=C(C=CC=C2)C2=N1 FDFQQENXEYGEML-UHFFFAOYSA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
239000002660 neuropeptide Y receptor antagonist Substances 0.000 description 1
210000004179 neuropil Anatomy 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
238000005457 optimization Methods 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000019809 paraffin wax Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
101150037969 pde-6 gene Proteins 0.000 description 1
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
229960002847 prasterone Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
230000002360 prefrontal effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
230000005180 public health Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003246 quinazolines Chemical class 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
231100000272 reduced body weight Toxicity 0.000 description 1
230000004648 relaxation of smooth muscle Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000004332 silver Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
201000002859 sleep apnea Diseases 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
150000003413 spiro compounds Chemical class 0.000 description 1
BYOIMOJOKVUNTP-UHFFFAOYSA-N spiro[1h-2-benzofuran-3,4'-piperidine] Chemical compound C12=CC=CC=C2COC21CCNCC2 BYOIMOJOKVUNTP-UHFFFAOYSA-N 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000001977 striatum neuron Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000010408 sweeping Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
229940127230 sympathomimetic drug Drugs 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
239000003749 thyromimetic agent Substances 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
229940117972 triolein Drugs 0.000 description 1
238000001665 trituration Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000001030 ventral striatum Anatomy 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1